KRAS Mutations in Metastatic CRC Predict Survival Benefit of Chemo Combo
Codon-specific KRAS mutations are predictive of an overall survival (OS) benefit for metastatic colorectal cancer (mCRC) patients treated with trifluridine-tipiracil (FTD/TPI; Lonsurf), according to a genomics-based analysis. After identifying biomarkers of resistance and validating the findings in a real-world dataset, researchers showed that patients with KRAS G12-mutant tumors in the phase III RECOURSE trial achieved […]